Published in Exp Dermatol on August 01, 1996
Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol (2004) 1.39
IL-1R1 signaling facilitates Munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation. J Invest Dermatol (2013) 0.89
cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci U S A (1991) 2.16
Cyclosporine improves psoriasis in a double-blind study. JAMA (1986) 1.95
Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol (1993) 1.86
Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol (1989) 1.60
Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol (1993) 1.55
Monoclonal antibodies to Brucella surface antigens associated with the smooth lipopolysaccharide complex. Am J Vet Res (1984) 1.54
Cyclosporine in dermatology. J Am Acad Dermatol (1989) 1.50
Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol (1998) 1.50
Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol (2000) 1.46
IL-12 synthesis by human Langerhans cells. J Immunol (1996) 1.43
Characterization of monoclonal antibodies directed against swine leukocytes. Vet Immunol Immunopathol (1986) 1.42
A pilot study of the effect of oral 8-methoxypsoralen and intraarticular ultraviolet light on rheumatoid synovitis. J Rheumatol (1995) 1.40
IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta. J Immunol (1990) 1.39
Lymphocytic infiltrates of the skin in association with cyclosporine therapy. J Am Acad Dermatol (1990) 1.39
Immunosuppression in a homosexual man with Kaposi's sarcoma. J Am Acad Dermatol (1982) 1.38
Expression of OKM5 antigen on epidermal cells in mycosis fungoides plaque stage. J Invest Dermatol (1988) 1.38
Melanophages in inflammatory skin disease demonstrate the surface phenotype of OKM5+ antigen-presenting cells and activated macrophages. J Am Acad Dermatol (1988) 1.38
Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol (1998) 1.36
The control of differentiation by the T complex. Immunol Rev (1977) 1.34
Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol (1990) 1.33
UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol (1990) 1.29
Linkage disequilibrium between H-2 and t complexes in chromosome 17 of the mouse. Nature (1975) 1.20
Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis (1999) 1.20
Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J Exp Med (1998) 1.18
Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells. J Invest Dermatol (1989) 1.17
Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch Dermatol Res (1989) 1.15
Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin. J Invest Dermatol (1991) 1.13
Cutaneous dermal Ia+ cells are capable of initiating delayed type hypersensitivity responses. J Invest Dermatol (1990) 1.13
CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J Immunol (1994) 1.12
Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol (1991) 1.09
Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J Invest Dermatol (1992) 1.09
Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest (1992) 1.09
Antigen-presenting OKM5+ melanophages appear in human epidermis after ultraviolet radiation. J Invest Dermatol (1986) 1.05
Reversal of immunosuppression inducible through ultraviolet-exposed skin by in vivo anti-CD11b treatment. J Immunol (1996) 1.04
T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol (1993) 1.03
Concurrent eosinophilic fasciitis and cutaneous T-cell lymphoma. Eosinophilic fasciitis as a paraneoplastic syndrome of T-cell malignant neoplasms? Arch Dermatol (1991) 1.03
Monocyte induction of IL-10 and down-regulation of IL-12 by iC3b deposited in ultraviolet-exposed human skin. J Immunol (1998) 1.02
Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol (1990) 1.02
Solar ultraviolet radiation and the risk of infectious disease: summary of a workshop. Photochem Photobiol (1995) 1.00
Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med (1993) 1.00
Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA (1991) 0.98
The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J Invest Dermatol (1998) 0.97
Neutrophils, differentiated macrophages, and monocyte/macrophage antigen presenting cells infiltrate murine epidermis after UV injury. J Invest Dermatol (1993) 0.96
Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study. J Am Acad Dermatol (1990) 0.94
In human dermis, ultraviolet radiation induces expansion of a CD36+ CD11b+ CD1- macrophage subset by infiltration and proliferation; CD1+ Langerhans-like dendritic antigen-presenting cells are concomitantly depleted. J Invest Dermatol (1995) 0.93
T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis. Arch Dermatol (1992) 0.93
In human skin, UVB initiates early induction of IL-10 over IL-12 preferentially in the expanding dermal monocytic/macrophagic population. J Invest Dermatol (1998) 0.93
Markedly diminished epidermal keratinocyte expression of intercellular adhesion molecule-1 (ICAM-1) in Sézary syndrome. JAMA (1989) 0.93
Human epidermal cells from ultraviolet light-exposed skin preferentially activate autoreactive CD4+2H4+ suppressor-inducer lymphocytes and CD8+ suppressor/cytotoxic lymphocytes. J Immunol (1988) 0.92
In vivo ultraviolet-exposed human epidermal cells activate T suppressor cell pathways that involve CD4+CD45RA+ suppressor-inducer T cells. J Immunol (1990) 0.92
Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: reduced expression of protein kinase C-beta II in psoriasis. J Invest Dermatol (1993) 0.91
Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest (1997) 0.91
The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today (1993) 0.91
Interleukin-1 in human skin: dysregulation in psoriasis. J Invest Dermatol (1990) 0.91
Woringer-Kolopp disease (localized pagetoid reticulosis) or unilesional mycosis fungoides? An analysis of eight cases with benign disease. Arch Dermatol (1995) 0.91
Evidence for postmeiotic effect of T factors causing segregation distortion in mouse. Nature (1975) 0.91
Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J Clin Invest (1998) 0.90
Evaluation of spleen lymphocyte responsiveness to a T-cell mitogen during early infection with larval Taenia taeniaeformis. Parasitol Res (1987) 0.90
Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol (2000) 0.89
Candida albicans and Candida krusei differentially induce human blood mononuclear cell interleukin-12 and gamma interferon production. Infect Immun (2000) 0.89
Fluorescence microscopic and flow cytometric analysis of bone marrow-derived cells in human epidermis: a search for the human analogue of the murine dendritic Thy-1+ epidermal cell. J Invest Dermatol (1985) 0.88
A clinical and histologic mycosis fungoides simulant occurring as a T-cell infiltrate coexisting with B-cell leukemia cutis. J Am Acad Dermatol (1995) 0.87
Phosphoinositide-mediated signal transduction in normal and psoriatic epidermis. J Invest Dermatol (1990) 0.87
Hyphae and yeasts of Candida albicans differentially regulate interleukin-12 production by human blood monocytes: inhibitory role of C. albicans germination. Infect Immun (2001) 0.87
A simple clinical scoring system to improve the sensitivity and standardization of the diagnosis of mycosis fungoides type cutaneous T-cell lymphoma: logistic regression of clinical and laboratory data. Br J Dermatol (2003) 0.86
Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol (1985) 0.86
UVB and UVC, but not UVA, potently induce the appearance of T6- DR+ antigen-presenting cells in human epidermis. J Invest Dermatol (1987) 0.86
Histocompatibility-2 system in wild mice. II. H-2 haplotypes of t-bearing mice. Transplantation (1976) 0.86
Immunogenetic analysis of H-2 mutations. V. Serological analysis of mutations H-2da, H-2ra, and H-2ka1. Transplantation (1976) 0.86
Human dermal fibroblast interleukin-1 receptor antagonist (IL-1ra) and interleukin-1 beta (IL-1 beta) mRNA and protein are co-stimulated by phorbol ester: implication for a homeostatic mechanism. J Invest Dermatol (1992) 0.86
Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen. J Am Acad Dermatol (1993) 0.85
Decreased number and function of antigen-presenting cells in the skin following application of irritant agents: relevance for skin cancer? J Invest Dermatol (1989) 0.85
Leukemic T cells from patients with cutaneous T-cell lymphoma demonstrate enhanced activation through CDw60, CD2, and CD28 relative to activation through the T-cell antigen receptor complex. J Invest Dermatol (1993) 0.85
Polyamine compartmentalization in various human disease states. Clin Chim Acta (1978) 0.85
Hyperstimulatory CD1a+CD1b+CD36+ Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis. J Immunol (1991) 0.85
Distinction of class II MHC+ Langerhans cell-like interstitial dendritic antigen-presenting cells in murine dermis from dermal macrophages. J Invest Dermatol (1994) 0.85
Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol (1993) 0.85
Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol (2012) 0.85
The potential supply of cadaveric kidneys for transplantation. Trans Am Soc Artif Intern Organs (1977) 0.85
The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol (1990) 0.85
Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice. Infect Immun (2001) 0.84